NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
AGENCY
HHS-NIH11
PROGRAM
Discretionary
AMOUNT
—
CLOSES
Feb 3, 2027
Description
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Eligibility
Special district governments; City or township governments; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Private institutions of higher education; Independent school districts; Small businesses; Public and State controlled institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Native American tribal governments (Federally recognized); State governments; For profit organizations other than small businesses
Contact
Additional details
- Funding instrument
- Grant
- Cost sharing required
- No
- Archived
- Mar 5, 2027
Opportunity number: PAR-25-026
Search this number on Grants.gov for the official listing.